Although the majority of diagnosed tumours express ER and PR, about 20–30% of cases express the hormonal receptors and HER-2, and are classified as luminal B-like (HER-2 positive), whereas those named HER-2 positive (non-luminal) only overexpress HER-2 [2,3,4,5]. Here, ERBB2 is linked to neoplasm.